Drugs / 6β-Naltrexol
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00829777 | Mar → Sep 2009 | opiate dependence | California Pacific Medical Center Research Institute | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 6β-Naltrexol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00829777 ↗ |
| Known as | AIKO-150 | “A Phase-I, Two-Stage, Double-Blind, Placebo-Controlled, Pharmacokinetic and Pharmacodynamic Trial of Low Doses of Intravenous 6β-Naltrexol (AIKO-150) in Opioid-Dependent Subjects.” NCT00829777 ↗ |
| Route | Intravenous | “with all subjects receiving oral Lactulose 10 GM plus IV escalating 6β-Naltrexol 0.05 mg, 0.15 mg, 0.5 mg with a randomized placebo” NCT00829777 ↗ |